Toyota|$17.77 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$27.33 (¥4,351)-0.32%▼ (in JPY terms)
SoftBank|$18.88 (¥3,006)-15.01%▼ (in JPY terms)
MUFG|$19.44 (¥3,095)-3.19%▼ (in JPY terms)
Keyence|$87.76 (¥13,970)-4.90%▼ (in JPY terms)
Nintendo|$56.36 (¥8,972)-3.59%▼ (in JPY terms)
NTT|$1.06 (¥168)-0.41%▼ (in JPY terms)
Takeda|$43.95 (¥6,996)+0.66%▲ (in JPY terms)
Tokyo Electron|$52.30 (¥8,325)-6.88%▼ (in JPY terms)
Recruit|$108.18 (¥17,220)-3.34%▼ (in JPY terms)
ITOCHU|$14.26 (¥2,270)-0.94%▼ (in JPY terms)
Honda|$11.06 (¥1,761)-1.65%▼ (in JPY terms)
Shin-Etsu|$33.21 (¥5,286)-4.40%▼ (in JPY terms)
Tokio Marine|$3.68 (¥586)+3.50%▲ (in JPY terms)
Fast Retailing|$519.92 (¥82,760)-0.73%▼ (in JPY terms)
Toyota|$17.77 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$27.33 (¥4,351)-0.32%▼ (in JPY terms)
SoftBank|$18.88 (¥3,006)-15.01%▼ (in JPY terms)
MUFG|$19.44 (¥3,095)-3.19%▼ (in JPY terms)
Keyence|$87.76 (¥13,970)-4.90%▼ (in JPY terms)
Nintendo|$56.36 (¥8,972)-3.59%▼ (in JPY terms)
NTT|$1.06 (¥168)-0.41%▼ (in JPY terms)
Takeda|$43.95 (¥6,996)+0.66%▲ (in JPY terms)
Tokyo Electron|$52.30 (¥8,325)-6.88%▼ (in JPY terms)
Recruit|$108.18 (¥17,220)-3.34%▼ (in JPY terms)
ITOCHU|$14.26 (¥2,270)-0.94%▼ (in JPY terms)
Honda|$11.06 (¥1,761)-1.65%▼ (in JPY terms)
Shin-Etsu|$33.21 (¥5,286)-4.40%▼ (in JPY terms)
Tokio Marine|$3.68 (¥586)+3.50%▲ (in JPY terms)
Fast Retailing|$519.92 (¥82,760)-0.73%▼ (in JPY terms)

2026-11-19 Eisai Co.,Ltd. “"Rekenbi®" presented 3 years of real-world clinical data at CTAD 2026—reporting new findings as the largest-scale analysis to date of the LEADER study, including amyloid removal effects in routine clinical practice, delay of progression to moderate or severe AD, expanded experience with subcutaneous administration as maintenance therapy, and additional analysis results by gender.”

2026-11-19 Eisai Co.,Ltd. “"Rekenbi®" presented 3 years of real-world clinical data at CTAD 2026—reporting new findings as the largest-scale analysis to date of the LEADER study, including amyloid removal effects in routine clinical practice, delay of progression to moderate or severe AD, expanded experience with subcutaneous administration as maintenance therapy, and additional analysis results by gender.”

コメントする